SLRX

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing effective treatments for cancers with unmet medical needs. It is developing treatments for cancers caused by dysregulated gene expression. The Company’s product portfolio includes seclidemstat, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options. The Company's pipeline consists of two primary compounds: SP-3164, a small-molecule protein degrader, and seclidemstat (SP-2577), a small-molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening.